Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) announced that the China National Intellectual Property Administration granted a Chinese patent titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells".
The patent (PCT/US2019/048400), developed by North Carolina State University, provides protection in China through August 27, 2039, subject to maintenance requirements, and covers a splice-switching oligonucleotide platform that selectively induces mast cell apoptosis.
Positive
- Chinese patent protection through August 27, 2039
- Platform patent covers splice-switching oligonucleotides inducing mast cell apoptosis
Negative
- Protection is subject to maintenance requirements, risking lapse if not maintained
News Market Reaction – HOTH
In the Mar 31 session, HOTH gained 9.12%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.8% during that session. Argus tracked a trough of -38.0% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.1x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | AI platform launch | Positive | -6.7% | Deployed OpenClaw AI platform to accelerate drug discovery across pipeline. |
| Mar 24 | Clinical PK update | Positive | -5.0% | Reported positive HT-001 PK, safety and clinical activity data in cancer patients. |
| Mar 10 | Preclinical metabolic data | Positive | +1.5% | Showed HT-VA improved lipid metabolism in female MASLD mouse model. |
| Mar 4 | Oncology preclinical data | Positive | +3.3% | Shared HT-KIT preclinical tumor suppression data and IND-enabling progress. |
| Feb 24 | Trial expansion | Positive | +5.0% | Expanded CLEER-001 Phase 2a trial after strong interim efficacy and safety signals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive, with three of five events seeing aligned positive price reactions and two showing selloffs despite constructive updates, suggesting occasional profit-taking or skepticism on good news.
Over the past few months, Hoth reported multiple positive developments across oncology and metabolic programs. On Feb 24, CLEER-001 Phase 2a interim data and a new site coincided with a 4.95% gain. Positive HT-KIT preclinical oncology data on Mar 4 and HT-VA MASLD preclinical results on Mar 10 also supported the story, with mixed price follow-through. Later, favorable HT-001 PK/safety data on Mar 24 and deployment of the OpenClaw™ AI platform on Mar 26 were followed by declines, highlighting uneven market confidence despite a steady stream of constructive R&D milestones leading into today’s patent news.
Key Terms
splice-switching oligonucleotides medical
apoptosis medical
mast cells medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Technology Selectively Shuts Down Cancer Reproducing Cells
Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells
The patent, originally filed under PCT Application No. PCT/US2019/048400 and developed by North Carolina State University, strengthens Hoth's intellectual property portfolio and provides protection in a key global market through August 27, 2039, subject to maintenance requirements.
The granted patent relates to a novel therapeutic platform utilizing splice-switching oligonucleotides designed to selectively induce apoptosis in mast cells, which play a central role in a variety of inflammatory and immunological conditions.
"This patent grant in
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-issuance-of-chinese-patent-for-cancer-celltargeting-technology-302729593.html
SOURCE Hoth Therapeutics, Inc.